Study Evaluating the Safety and Feasibility of Platelet-rich Plasma to Treat Facetogenic Low Back Pain

Lumbar Spondylosis Clinical Trial

Official title:

A Phase I Study Evaluating the Safety and Feasibility of Platelet-rich Plasma for the Treatment of Facetogenic Low Back Pain

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05250947
• Other study ID #: 18-011475
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 5, 2023
• Est. completion date: July 2024

Study information

• Verified date: June 2023
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to assess the safety of using the Angel Concentrated Platelet Rich Plasma System to process Platelet Rich Plasma (PRP) to treat arthritis of the low back (lumbar spondylosis).

Description:

This study is a pilot of the safety of using the FDA cleared Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set to process PRP to treat arthritis of the low back (lumbar spondylosis). Subjects will be screened at outpatient clinic visit appointments and interested qualified subjects will be consented and offered participation in this trial. Once consent has been obtained baseline values will be established and subjects will begin treatment and follow-up for the next 12 months. A final visit for evaluation and collection of lab samples will be conducted at the end of the study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 4
• Est. completion date: July 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years to 70 Years

Eligibility

Inclusion Criteria:

• Clinical and radiographic (MRI, CT or lumbar x-ray) evidence of symptomatic facet arthropathy involving the bilateral bottom two facets (e.g., L4-5 or L5-6 and L5-S1 or L6-S1).

• Positive response, defined according to current clinical standards for the diagnosis of facet-mediated low back pain as greater than or equal to 75% pain improvement (as reported by patient) to diagnostic medial branch nerve blocks, one block with lidocaine and the other with bupivacaine.

• Low back pain VAS score of greater than or equal to 5 at the clinical visit just prior to the first medial branch nerve block.

Exclusion Criteria:

• Prior facet related procedure (intraarticular corticosteroid injection, radiofrequency ablation (RFA)) in last 6 months or prior fusion in the bottom two facets.

• Current opioid use of greater than 50mg oral morphine milligram equivalents per day.

• No advanced imaging (MRI, CT or lumbar x-ray) of the lumbar spine within the last 6 months.

• BMI > 34.99 (WHO class I obesity).

• Active systemic or local infection as evidenced by fever >100.4 degrees Fahrenheit, or any other clinical signs or symptoms of infection within 24 hours of the procedure.

• On anticoagulation drug and has been on hold for less than 7 days prior to the investigational procedure.

• Imaging evidence of high likelihood of failure for intra-articular injection in the opinion of the PI or delegate review of MRI, CT or lumbar x-ray imaging.

• History of chronic thrombocytopenia (or pre-operative platelet count less than 195,000 per µl).

• Undergoing chemotherapy at time of injection.

• Pregnant or breastfeeding.

• Use of illicit drugs within 30 days prior to study entry.

• NSAID use during the pre-procedural period (one week before Treatment Day 0).

• Preoperative hematocrit less than 36%.

• History of hemodynamic instability or inability to maintain stable oncotic pressure.

• History of prolonged clotting times.

• Prior history of lumbar procedure.

• Redness, swelling, rash or other concerning lesions at the injection site just prior to the procedure.

• Prior history of allergy to lidocaine or other local anesthetic agent.

Related Conditions & MeSH terms

• Back Pain
• Low Back Pain
• Lumbar Spondylosis
• Spondylosis

Intervention

Device:
• Angel® Concentrated Platelet Rich Plasma System
Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP.

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Matthew Pingree

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of adverse device effects	Adverse device effects related to the processing of the platelet rich plasma product (such as hardware failures/malfunctions, software errors, disposable set equipment malfunctions, processing errors, automatic self-test/calibration errors, variations in hematocrit level in final product, variations in total volume of PRP concentrate produced, etc.)	Day 0 (Day of procedure)
Primary	Number of suspected acute adverse reactions to the treatment	Suspected adverse reactions to the treatment based on evaluations including follow-up physical examinations, labs and assessment of clinical signs and symptoms.	Day 0 to Day 14

External Links

•   Mayo Clinic Clinical Trials